Harrow Health, Inc. (HROW) introduced its Direct‑to‑Prescriber (DTP) cash‑pay offering, PharmaPack, on February 17, 2026. The program expands the company’s commitment to providing affordable, FDA‑approved ophthalmic products as alternatives to off‑label compounded formulations.
PharmaPack kits are initially available in California, Mississippi, Arkansas, Connecticut, and Alabama, with plans to expand nationwide in the coming weeks. Each kit contains FDA‑approved drugs such as NEVANAC, TOBRADEX ST, and MAXITROL, and is priced at 100% transparent, cash‑pay rates designed to reduce insurance‑related administrative complexity and regulatory risk for prescribers.
The launch is intended to give eye care professionals a reliable, branded alternative to compounded products for infection control and pain management associated with cataract surgery. By offering a cash‑pay model, Harrow Health removes the need for insurance billing and the associated compliance hurdles, allowing prescribers to focus on patient care rather than paperwork.
Management highlighted the strategic importance of the initiative. “Harrow’s PharmaPack program addresses a long‑standing challenge in ophthalmology—providing patients with FDA‑approved therapies that are both reliable and affordable,” said Dr. Scott Spector, MD. “The combination of trusted branded products, pricing transparency, and compelling cash‑pay prices is encouraging and supports complexity‑free prescribing.”
Dr. Maria Pribis, OD, added that “Access to FDA‑approved therapies at affordable, transparent prices is something optometrists have been asking for. PharmaPack helps close that gap by making high‑quality branded products more attainable for everyday patient care.”
The launch aligns with Harrow Health’s broader strategy to expand its FDA‑approved product portfolio and reduce reliance on its compounding business. The company has reported a 27.4% compound annual growth rate in revenue, but has struggled with profitability, posting a negative EPS of –$0.15 and a net margin of –2% in fiscal 2024. Gross margin remains strong at 74.56%, and liquidity is solid, though the debt‑to‑equity ratio is high.
Harrow Health’s Q3 2025 results showed a 45% year‑over‑year increase in revenue to $71.6 million, and the company updated its full‑year 2025 revenue guidance to $270 million–$280 million. The PharmaPack launch is expected to contribute to this growth trajectory by capturing market share from compounded products and appealing to prescribers seeking transparent, cash‑pay options.
The company’s strategy to offer branded, FDA‑approved products directly to prescribers is designed to mitigate regulatory risk and administrative burden, positioning Harrow Health to compete more effectively in the ophthalmic market.
The introduction of PharmaPack is a significant operational milestone that could influence Harrow Health’s future revenue mix and market positioning, making it a noteworthy development for investors and industry observers.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.